In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). | In a mixed interim data drop, Arcturus ...

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found "potentially promising." ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shares sank 50% on Wednesday after the company reported interim Phase 2 ...

Arcturus Therapeutics Holdings recently saw its consensus analyst price target lowered from $69.89 to $65.88, reflecting a modest dialing back of expectations about its future share value. This ...

In the fast-evolving field of medical science, a new artificial intelligence model may be about to change the way mRNA-based drugs and vaccines are designed. Developed through a collaboration between ...

N 6-methyladenosine (m 6 A) is the most extensive studied RNA modification across various species, and the important effect of m 6 A modification in immune system has been revealed in distinct ...

Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients but no initial FEV₁ improvement.

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

The mRNA therapeutics market offers key opportunities in developing vaccines and treatments for chronic and infectious diseases, driven by successful clinical trials and increased government and ...